NCT07409272 2026-04-16
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
65 trialsNCT07522073 2026-04-13
DAWN-303
Incyte Corporation
Phase 3 Recruiting
NCT07252232 2026-04-06
RASolute 304
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT07491445 2026-04-06
RASolute 303
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT06608927 2026-04-01
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT06861088 2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3 Recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07138846 2025-08-24
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
Shanghai Miracogen Inc.
Phase 3 Not yet recruiting
NCT07066098 2025-08-15
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Recruiting
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT03899636 2025-02-12
DIRECT
Angiodynamics, Inc.
Phase 3 Active not recruiting
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT04300114 2024-03-28
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT04329949 2023-11-18
RELIANT
Corcept Therapeutics
Phase 3 Terminated
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02184195 2023-09-13
POLO
AstraZeneca
Phase 3 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT03126435 2023-05-06
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
SynCore Biotechnology Co., Ltd.
Phase 3 Completed
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04969731 2021-11-22
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
GC Cell Corporation
Phase 3 Recruiting
NCT01956812 2021-08-16
PANCRIT®-1
Gilead Sciences
Phase 3 Terminated
NCT04151719 2021-05-07
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 3 Withdrawn
NCT03766295 2020-12-08
Masitinib Plus Gemcitabine in Pancreatic Cancer
AB Science
Phase 3 Completed
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT01072981 2020-05-28
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Lumos Pharma
Phase 3 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02043288 2020-04-15
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Orient Europharma Co., Ltd.
Phase 3 Completed
NCT00844649 2019-11-25
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Celgene
Phase 3 Completed
NCT02117479 2019-03-26
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Incyte Corporation
Phase 3 Terminated
NCT00789633 2018-12-17
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
AB Science
Phase 3 Completed
NCT02119663 2018-02-13
A Study of Ruxolitinib in Pancreatic Cancer Patients
Incyte Corporation
Phase 3 Terminated
NCT00040183 2018-01-10
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Astellas Pharma Inc
Phase 3 Completed
NCT03200821 2017-06-27
An Open Label Study to Evaluate G17DT Compared to Gemcitabine
Cancer Advances Inc.
Phase 3 Completed
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00312013 2017-03-23
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
GlaxoSmithKline
Phase 3 Completed
NCT02854072 2016-11-22
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Samsung Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01360853 2016-08-04
ONTRAC
Traws Pharma, Inc.
Phase 3 Completed
NCT00637728 2016-06-23
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Par Pharmaceutical, Inc.
Phase 3 Terminated
NCT01494506 2016-06-17
NAPOLI-1
Merrimack Pharmaceuticals
Phase 3 Completed
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT00417209 2016-06-03
PAPRIKA
Sanofi
Phase 3 Completed
NCT00602745 2016-05-26
S-1 Pancreas
Sanofi
Phase 3 Terminated
NCT01121848 2014-10-27
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Sanofi
Phase 3 Completed
NCT01214720 2014-08-13
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed